New product line C-Trap ‘Edge’ adds important capabilities relevant for surface assays, which are of increasing importance in biophysical and biology research.
j.yeh18 February 2022
Using cell avidity measurements and traditional immuno-assays, the researchers successfully demonstrated that co-expression of costimulatory receptors along with an FDA approved BCMA and CD19 CAR can improve both durability of potential treatments as well as persistence for common blood cancers.
j.yeh23 January 2022
The C-Trap will support the research of Prof. Michael O’Donnell to investigate the mechanisms of DNA replication. Between O’Donnell and his collaborator Prof Shixin Liu, Rockefeller University will use the C-Trap to unveil the mechanisms of many types of enzymes, such as multi-protein DNA replicating machines of bacteria and eukaryotes.
j.yeh11 January 2022
LUMICKS announced today that two major centers of excellence in cancer immunology, Fred Hutchinson Cancer Research Center and Oxford University, have adopted the z-Movi Cell Avidity Analyzer instrument for the development of promising immunotherapeutic strategies.
j.yeh10 January 2022
We are pleased to announce key appointments to our Scientific Advisory Board, with both new members strategically selected to help support our growth strategy.
j.yeh15 December 2021
Jos Maas joins as new general manager of Dynamic Single Molecule business and Geerte Hesen joins as new General Counsel. They both bring strong managerial acumen and a track record of supporting innovation.
j.yeh17 November 2021
We are excited to announnce that Joshua Young will join our leadership team to lead the company’s Investor Relations, Communications and Strategy functions.
j.yeh27 October 2021
We are pleased to announce two key appointments to our Board of Directors that bring a combined 40 years of executive-level experience in human resources and finance. Melissa McLaughlin and Solange Glaize are the newest addition to LUMICKS Board, each offering invaluable insight that will help pave the way for…
j.yeh30 September 2021
We are pleased to announce the appointment of Dr. Paul Wheeler to its leadership team, effective July 1, 2021. In the newly-created position of Chief Commercial Officer, Dr. Wheeler will lead LUMICKS aggressive commercial growth strategy by building a stronger market presence, developing highly-effective sales teams, and focusing on enhanced…
j.yeh17 August 2021
